Pancreatic and hepatobiliary cancers, including hepatocellular carcinoma (HCC), cholangiocarcinoma, and gallbladder carcinoma, are lethal malignancies with a high mortality rate, a poor survival rate, and a poor prognosis. Both have seen an increase in their incidence worldwide, with a significant increment in the impact on the different health systems. Nowadays, potential curative treatments are based on surgical resection combined with adjuvant systemic chemotherapy. However there is a high recurrence rate, and many patients are typically diagnosed at advanced stages, causing further challenges. Therefore, there is significant research exploring alternative strategies to improve the survival rate of patients.
Immunotherapy for pancreatic and hepatobiliary cancers is a promising alternative therapeutic approach that is currently being highly explored. Although the previous applications of immunotherapies with checkpoint inhibitors had poor results in pancreatobilliary tumors, a better understanding of the interactions between the immune system present on the tumour microenvironment and the tumour itself is of outstanding interest to improve the results of the available immune treatments. Also, this knowledge will increase the possibility of developing other approaches (vaccine developments (with different technologies like the application of neo-antigens, or miRNA), bispecific antibodies, cell therapies, or combinations of these different approaches, including the association of immune treatment with chemotherapy.
The aim of this Research Topic is to explore how immunotherapy and combination strategies can improve the survival rate for pancreatic and hepatobiliary cancer patients. We propose two key themes: description of new mechanisms associated with tumoral resistance to immunotherapies and potential treatments to solve those resistance and the description of the application of new treatments based on different approaches using immunotherapy. We welcome Original Research, Reviews, Systematic Reviews, Meta-analysis and Mini-Reviews.
Pancreatic and hepatobiliary cancers, including hepatocellular carcinoma (HCC), cholangiocarcinoma, and gallbladder carcinoma, are lethal malignancies with a high mortality rate, a poor survival rate, and a poor prognosis. Both have seen an increase in their incidence worldwide, with a significant increment in the impact on the different health systems. Nowadays, potential curative treatments are based on surgical resection combined with adjuvant systemic chemotherapy. However there is a high recurrence rate, and many patients are typically diagnosed at advanced stages, causing further challenges. Therefore, there is significant research exploring alternative strategies to improve the survival rate of patients.
Immunotherapy for pancreatic and hepatobiliary cancers is a promising alternative therapeutic approach that is currently being highly explored. Although the previous applications of immunotherapies with checkpoint inhibitors had poor results in pancreatobilliary tumors, a better understanding of the interactions between the immune system present on the tumour microenvironment and the tumour itself is of outstanding interest to improve the results of the available immune treatments. Also, this knowledge will increase the possibility of developing other approaches (vaccine developments (with different technologies like the application of neo-antigens, or miRNA), bispecific antibodies, cell therapies, or combinations of these different approaches, including the association of immune treatment with chemotherapy.
The aim of this Research Topic is to explore how immunotherapy and combination strategies can improve the survival rate for pancreatic and hepatobiliary cancer patients. We propose two key themes: description of new mechanisms associated with tumoral resistance to immunotherapies and potential treatments to solve those resistance and the description of the application of new treatments based on different approaches using immunotherapy. We welcome Original Research, Reviews, Systematic Reviews, Meta-analysis and Mini-Reviews.
Please note: manuscripts consisting solely of bioinformatics or computational analysis of public genomic or transcriptomic databases which are not accompanied by validation (independent cohort or biological validation in vitro or in vivo) are out of scope for this section and will not be accepted as part of this Research Topic.
Pancreatic and hepatobiliary cancers, including hepatocellular carcinoma (HCC), cholangiocarcinoma, and gallbladder carcinoma, are lethal malignancies with a high mortality rate, a poor survival rate, and a poor prognosis. Both have seen an increase in their incidence worldwide, with a significant increment in the impact on the different health systems. Nowadays, potential curative treatments are based on surgical resection combined with adjuvant systemic chemotherapy. However there is a high recurrence rate, and many patients are typically diagnosed at advanced stages, causing further challenges. Therefore, there is significant research exploring alternative strategies to improve the survival rate of patients.
Immunotherapy for pancreatic and hepatobiliary cancers is a promising alternative therapeutic approach that is currently being highly explored. Although the previous applications of immunotherapies with checkpoint inhibitors had poor results in pancreatobilliary tumors, a better understanding of the interactions between the immune system present on the tumour microenvironment and the tumour itself is of outstanding interest to improve the results of the available immune treatments. Also, this knowledge will increase the possibility of developing other approaches (vaccine developments (with different technologies like the application of neo-antigens, or miRNA), bispecific antibodies, cell therapies, or combinations of these different approaches, including the association of immune treatment with chemotherapy.
The aim of this Research Topic is to explore how immunotherapy and combination strategies can improve the survival rate for pancreatic and hepatobiliary cancer patients. We propose two key themes: description of new mechanisms associated with tumoral resistance to immunotherapies and potential treatments to solve those resistance and the description of the application of new treatments based on different approaches using immunotherapy. We welcome Original Research, Reviews, Systematic Reviews, Meta-analysis and Mini-Reviews.
Pancreatic and hepatobiliary cancers, including hepatocellular carcinoma (HCC), cholangiocarcinoma, and gallbladder carcinoma, are lethal malignancies with a high mortality rate, a poor survival rate, and a poor prognosis. Both have seen an increase in their incidence worldwide, with a significant increment in the impact on the different health systems. Nowadays, potential curative treatments are based on surgical resection combined with adjuvant systemic chemotherapy. However there is a high recurrence rate, and many patients are typically diagnosed at advanced stages, causing further challenges. Therefore, there is significant research exploring alternative strategies to improve the survival rate of patients.
Immunotherapy for pancreatic and hepatobiliary cancers is a promising alternative therapeutic approach that is currently being highly explored. Although the previous applications of immunotherapies with checkpoint inhibitors had poor results in pancreatobilliary tumors, a better understanding of the interactions between the immune system present on the tumour microenvironment and the tumour itself is of outstanding interest to improve the results of the available immune treatments. Also, this knowledge will increase the possibility of developing other approaches (vaccine developments (with different technologies like the application of neo-antigens, or miRNA), bispecific antibodies, cell therapies, or combinations of these different approaches, including the association of immune treatment with chemotherapy.
The aim of this Research Topic is to explore how immunotherapy and combination strategies can improve the survival rate for pancreatic and hepatobiliary cancer patients. We propose two key themes: description of new mechanisms associated with tumoral resistance to immunotherapies and potential treatments to solve those resistance and the description of the application of new treatments based on different approaches using immunotherapy. We welcome Original Research, Reviews, Systematic Reviews, Meta-analysis and Mini-Reviews.
Please note: manuscripts consisting solely of bioinformatics or computational analysis of public genomic or transcriptomic databases which are not accompanied by validation (independent cohort or biological validation in vitro or in vivo) are out of scope for this section and will not be accepted as part of this Research Topic.